Lineage Cell Therapeutics Reports Significant Progress
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a pioneering biotechnology firm specializing in allogeneic cell therapies for unmet medical needs, has achieved a notable milestone with the completion of the second tranche of its previously announced registered direct offering. This initiative is pivotal in bolstering the company’s growth trajectory and expanding its capacity to develop transformative therapies.
Details of the Second Tranche Offering
Through this latest financial maneuver, Lineage secured an additional $6 million in gross proceeds, building on the initial $24 million garnered during the first tranche. This brings the total amount raised in the offering to an impressive $30 million. Furthermore, there's potential to generate up to an additional $36 million through the exercise of clinical milestone-linked warrants associated with the offering, reflecting the company’s ambition to fund its innovative pipeline effectively.
Shareholder Approval and Warrant Issuance
The successful closing of the second tranche included obtaining critical shareholder approval, which is a requirement under applicable NYSE American regulations. Specifically, Lineage shareholders granted approval for the issuance of 7,894,737 common shares alongside warrants to purchase an equal number of common shares. This was made at a combined purchase price of $0.76 per share and warrant to Broadwood Partners, L.P., associated with Neal Bradsher, a current member of Lineage’s board.
Warrant Details and Exercise Conditions
The warrants granted to Broadwood Partners are structured to begin their exercise period on May 21, 2025. Each warrant allows the holder to purchase one common share at an exercise price of $0.91. They will remain valid until either May 21, 2028, or 90 days after the public announcement of intent to advance OpRegen into a multi-center phase 2 or 3 clinical trial.
Regulatory Framework for the Offering
The securities provided in this offering were made possible through a registered direct offering under a shelf registration statement (File No. 333-277758) filed with the SEC. This pathway is designed to streamline the process for public companies to raise capital. Lineage has complied with all necessary regulations, ensuring that investors have access to detailed information about the offering through the appropriate SEC filings.
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is fundamentally reshaping the landscape of cell therapy. The company is dedicated to addressing significant medical needs through its innovative technologies. Its processes involve the creation of specialized human cells that mimic the natural functions found in the human body. This technology is essential for developing therapies that aim to replace or restore damaged cells due to various conditions, including degenerative diseases, trauma, and aging.
Research and Development Pipeline
Lineage’s innovative pipeline is particularly concentrated on neuroscience. Their key projects include OpRegen, which is in phase 2a for treating geographic atrophy; OPC1, targeting spinal cord injuries; and ReSonance™, which addresses auditory neuropathy. Additionally, the research includes PNC1 for vision restoration and RND1, a hypoimmune stem cell line, showcasing the breadth of their therapeutic targets.
Frequently Asked Questions
What is the purpose of the recent offering by Lineage?
The recent offering aims to secure funds for advancing their innovative cell therapies, particularly within the neuroscience sector.
What is Lineage Cell Therapeutics known for?
Lineage is recognized for its development of “off-the-shelf” cell therapies, addressing significant unmet medical needs through proprietary technology.
How much funding has Lineage raised in total from this offering?
With the completion of the first and second tranches, Lineage has raised a total of $30 million, with the potential for additional funds through warrants.
When can the warrants issued by Lineage be exercised?
Warrants can be exercised starting May 21, 2025, and will remain valid until either May 21, 2028, or 90 days after a significant clinical trial announcement.
What are the key projects in Lineage's pipeline?
Lineage's pipeline includes therapies for retinal conditions, spinal cord injuries, auditory neuropathy, and restoring vision, showcasing their diverse research efforts.
